Engineered biomaterial promotes formation of cancer-fighting immune cell clusters
But here's where it gets controversial... The key to unlocking the body's natural cancer-fighting power might lie in the intricate dance of immune cell clusters, or TLSs. These structures, which form within tumors, are like secret weapons that help the immune system recognize and attack cancer cells. However, many tumors lack these structures, which can limit the effectiveness of immunotherapy. So, how can we harness the power of TLSs to improve cancer treatment?
Researchers at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of TLSs. These immune cell clusters are increasingly linked to improved outcomes and treatment responses in cancer. The study, published in the Proceedings of the National Academy of Sciences, offers a new approach to understanding and potentially harnessing the power of TLSs for cancer treatment.
TLSs are specialized immune structures that sometimes form within tumors, helping the immune system recognize and attack cancer cells. However, many tumors lack these structures, which can limit the effectiveness of immunotherapy. Understanding how TLSs form and function has been challenging because traditional laboratory models cannot easily reproduce them.
Using an innovative approach, researchers created a biodegradable, injectable hydrogel that slowly releases immune-signaling molecules, including chemokines and cytokines, beneath the skin. These signals attract key immune cells such as T cells and B cells to the injection site, where they self-organize into TLS-like structures. When tested in mice, these induced immune clusters supported the activation of tumor-targeting T cells and slowed tumor growth.
But here's the part most people miss... The origins and functions of TLSs in antitumor immunity remain poorly understood, mainly because suitable mouse models have been lacking. This is where the new biomaterial-based system comes in. It induces TLS-like structures in a controlled way, which can be used both as preclinical models to study how TLSs form and function within tumors and as platforms to explore new therapeutic strategies that harness these structures to boost antitumor immunity.
Q&A with Rana Falahat, Ph.D., lead author and research scientist in the Immuno-Oncology Program at Moffitt.
Why are TLSs such an important focus in cancer immunology right now?
TLSs are increasingly shown to associate with better patient outcomes and improved responses to immunotherapies, making them a key focus in cancer immunology research today.
What challenges exist in studying TLSs in the lab, and how does your model help overcome those challenges?
The origins and functions of TLSs in antitumor immunity remain poorly understood, mainly because suitable mouse models have been lacking. In this study, we developed a biomaterial-based system that induces TLS-like structures in a controlled way, which can be used both as preclinical models to study how TLSs form and function within tumors and as platforms to explore new therapeutic strategies that harness these structures to boost antitumor immunity.
Can you explain, in simple terms, how your biomaterial system works?
We designed biodegradable materials that release immune-signaling molecules, such as chemokines and cytokines, after being injected under the skin. These signals attract immune cells, like T cells and B cells, to the site, where they begin to organize into structures that resemble TLSs found in tumors, allowing us to study how these structures form and function.
How might this research eventually benefit cancer patients, especially those whose tumors lack TLSs?
Tumors without TLSs often resist immunotherapy. By learning how to trigger TLS formation, we hope to help the immune system better recognize and attack these tumors, improving treatment options for patients who currently have limited responses to immunotherapies.
This study was supported by the National Cancer Institute (P30-CA076292, P50-CA168536), the CJG Fund, Chris Sullivan Fund, V Foundation, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and the Melanoma Research Foundation.
And this is the part most people miss... This research raises important questions about the role of TLSs in cancer immunology and the potential for new therapeutic strategies. It also highlights the importance of understanding the complex interplay between the immune system and cancer. So, what do you think? Do you agree or disagree with the findings? Share your thoughts in the comments below!
